| Literature DB >> 20075157 |
Cyrus Khandanpour1, Christian Thiede, Peter J M Valk, Ehssan Sharif-Askari, Holger Nückel, Dietmar Lohmann, Bernhard Horsthemke, Winfried Siffert, Andreas Neubauer, Karl-Heinz Grzeschik, Clara D Bloomfield, Guido Marcucci, Kati Maharry, Marilyn L Slovak, Bert A van der Reijden, Joop H Jansen, Hans K Schackert, Khashayar Afshar, Susanne Schnittger, Justine K Peeters, Frank Kroschinsky, Gerhard Ehninger, Bob Lowenberg, Ulrich Dührsen, Tarik Möröy.
Abstract
The GFI1 gene encodes a transcriptional repressor, which regulates myeloid differentiation. In the mouse, Gfi1 deficiency causes neutropenia and an accumulation of granulomonocytic precursor cells that is reminiscent of a myelodysplastic syndrome. We report here that a variant allele of GFI1 (GFI1(36N)) is associated with acute myeloid leukemia (AML) in white subjects with an odds ratio of 1.6 (P < 8 x 10(-5)). The GFI1(36N) variant occurred in 1806 AML patients with an allele frequency of 0.055 compared with 0.035 in 1691 healthy control patients in 2 independent cohorts. We observed that both GFI1 variants maintain the same activity as transcriptional repressors but differ in their regulation by the AML1/ETO (RUNX1/RUNX1T1) fusion protein produced in AML patients with a t(8;21) translocation. AML1/ETO interacts and colocalizes with the more common GFI1(36S) form in the nucleus and inhibits its repressor activity. However, the variant GFI1(36N) protein has a different subnuclear localization than GFI1(36S). As a consequence, AML1/ETO does not colocalize with GFI1(36N) and is unable to inhibit its repressor activity. We conclude that both variants of GFI1 differ in their ability to be regulated by interacting proteins and that the GFI1(36N) variant form exhibits distinct biochemical features that may confer a predisposition to AML.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20075157 PMCID: PMC2919174 DOI: 10.1182/blood-2009-08-239822
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113